A 1-Year Open-Label Safety Extension Study of Pregabalin (CI-1008) in Patients With Anxiety Disorders

Femme et Homme

| Pays :
| Organes :
| Spécialités :

Extrait

Main objective : • To evaluate under open-label conditions the long-term safety and tolerability of pregabalin in doses ranging from 150 to 600 mg/day.

Critère d'inclusion

Generalized Anxiety Disorder

Liens

euctr
ictrp